New inhaled drug SYH2059 begins first human safety tests
NCT ID NCT07510958
First seen Apr 10, 2026 · Last updated Jun 20, 2026 · Updated 14 times
Summary
This Phase 1 trial will test the safety and tolerability of an inhaled drug called SYH2059 in 84 healthy adults. Participants will receive either single or multiple doses of the drug or a placebo. The study aims to understand how the body processes the drug and whether it causes any side effects. Since this is an early-stage trial in healthy people, it does not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYH2059 powder for inhalation
What could go wrong
This is a very early Phase 1 study in healthy people, so it cannot show any treatment effect. The drug may prove unsafe or ineffective in future trials.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.